Condition: Lymphoblastic Leukemia · Lymphoblastic Leukemia in Children · Lymphoblastic Leukemia, Acute Adult · Sponsor: KK Women's and Children's Hospital
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
This description comes directly from the study's public registry record.
Shui Yen Soh, MD · +65 6394 1045 · soh.shui.yen@singhealth.com.sg
Germaine Liew, BS · +65 6394 5025 · germaine.liew.shimin@singhealth.com.sg
Always discuss trial participation with your own doctor first.
| Singapore General Hospital | Singapore, Singapore | Recruiting |
| KK Women's and Children's Hospital | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05648019